Clearside closes patient enrollment in trial for diabetic macular edema therapy

Clearside Biomedical (NSDQ:CLSD) said today that it finished enrollment for the Phase 1/2 study of CLS-TA in patients with diabetic macular edema. The Hulk trial is designed to evaluate the safety and efficacy of a suprachoroidal injection of its suspension formulation of a corticosteroid, triamcinolone acetonide, with and without an intravitreal injection of Eylea in DME patients. The Alpharetta, Ga.-based company said it expects preliminary results from the study in the 2nd half of this year. Get the full story at our sister site, Drug Delivery Business News. The post Clearside closes patient enrollment in trial for diabetic macular edema therapy appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Clearside Biomedical Source Type: news